Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Deuterated alpha-linolenic acid (RT011) is a polyunsaturated fatty acid (PUFA) in which the hydrogen atoms at the bis-allylic C11 position have been replaced with deuterium. This modification leverages the **Kinetic Isotope Effect (KIE)** to strengthen the carbon-deuterium bonds, making the molecule significantly more resistant to non-enzymatic lipid peroxidation. In neurodegenerative and retinal diseases, the accumulation of lipid peroxides and reactive aldehydes (such as 4-hydroxynonenal) triggers ferroptosis and protein aggregation. By incorporating into cellular membranes, deuterated linolenic acid prevents the self-sustaining chain reaction of lipid autoxidation, thereby protecting cells from oxidative damage and membrane disruption. It has been primarily developed for the treatment of ophthalmic conditions like dry age-related macular degeneration (AMD) and Stargardt disease, as well as broader neurodegenerative pathologies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on deuterated alpha-linolenic acid.